BIOMAX SUPPORTS EU-PROJECT PREPARE IN PATHOBIOLOGY RESEARCH AGAINST SARS-CoV-2
COVID-19/SARS-CoV-2 has switched the EU-project PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics) into Outbreak Mode. Its network is now implementing trials to answer the most urgent clinical questions. As partner in PREPARE Biomax is supporting research on the pathobiology of SARS-CoV-2 by applying its scientific assistant AILANI to currently available information. In addition an emergency disease map project is in preparation to integrate and structure information on all human coronaviruses and enable comparative pathobiology research as well as improve vaccine research. Finally Biomax makes available its System Medicine implementation of the BioXM Knowledge Management to support research into patient stratification and individualised treatment decisions.
BIOMAX SUPPORTS EU-PROJECT PREPARE IN PATHOBIOLOGY RESEARCH AGAINST SARS-CoV-2
COVID-19/SARS-CoV-2 has switched the EU-project PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics) into Outbreak Mode. Its network is now implementing trials to answer the most urgent clinical questions. As partner in PREPARE Biomax is supporting research on the pathobiology of SARS-CoV-2 by applying its scientific assistant AILANI to currently available information. In addition an emergency disease map project is in preparation to integrate and structure information on all human coronaviruses and enable comparative pathobiology research as well as improve vaccine research. Finally Biomax makes available its System Medicine implementation of the BioXM Knowledge Management to support research into patient stratification and individualised treatment decisions.
BIOMAX INVESTS IN CLINICAL DECISION SUPPORT SYSTEMS FOR NEUROLOGICAL AND MENTAL DISORDERS
With support from the European commission, the German Ministry of Science and the Bavarian Ministry of Economy, Biomax is investing into three outstanding projects on the development of clinical decision support systems (CDSS) for neurological and mental disorders, MS-CONNECT, DEVoTED and TranSYS. In TranSYS and DEVoTED, Biomax partners up with the Max-Planck-Institute for Psychiatry in Munich to identify patient subgroups related to treatment resistant depression and to predict the individual treatment success. Furthermore, Biomax leads the MS-CONNECT project, in which we aim to develop a CDSS for enhanced characterization of multiple sclerosis patients. Together with VU Medical Center Amsterdam and University Basel, Biomax brings its lighthouse technology NeuroXM™ Brain Science Suite into clinical application to predict disease progression of MS patients based on a fully automated quantification of connectomes — the wiring diagram of the patients' brains.
BIOMAX INVESTS IN CLINICAL DECISION SUPPORT SYSTEMS FOR NEUROLOGICAL AND MENTAL DISORDERS
With support from the European commission, the German Ministry of Science and the Bavarian Ministry of Economy, Biomax is investing into three outstanding projects on the development of clinical decision support systems (CDSS) for neurological and mental disorders, MS-CONNECT, DEVoTED and TranSYS. In TranSYS and DEVoTED, Biomax partners up with the Max-Planck-Institute for Psychiatry in Munich to identify patient subgroups related to treatment resistant depression and to predict the individual treatment success. Furthermore, Biomax leads the MS-CONNECT project, in which we aim to develop a CDSS for enhanced characterization of multiple sclerosis patients. Together with VU Medical Center Amsterdam and University Basel, Biomax brings its lighthouse technology NeuroXM™ Brain Science Suite into clinical application to predict disease progression of MS patients based on a fully automated quantification of connectomes — the wiring diagram of the patients' brains.
In February 2020 Biomax held the first of a total of three webinars on semantic search about AILANI for the life science sector.
The first webinar primarily addressed the needs of users in the agrotech environment. During the live presentation, Dr. Sascha Losko, Director Product Management and Dr. Mariana Mondragón-Palomino, Project Manager at Biomax Informatics, presented the semantic search platform AILANI and introduced various use cases for the agrotech sector referring to sample questions like:
- Which genes confer rice tolerance to salt stress?
- What fertilizer treatment increases soil microbial diversity?
- How to reduce acrylamide content in processed foods?
After the webinar all participants had the possibility to request free access to test the platform for their individual needs.
A recording of the webinar is now available on the Biomax Website or in our brand-new YouTube Channel.
In February 2020 Biomax held the first of a total of three webinars on semantic search about AILANI for the life science sector.
The first webinar primarily addressed the needs of users in the agrotech environment. During the live presentation, Dr. Sascha Losko, Director Product Management and Dr. Mariana Mondragón-Palomino, Project Manager at Biomax Informatics, presented the semantic search platform AILANI and introduced various use cases for the agrotech sector referring to sample questions like:
- Which genes confer rice tolerance to salt stress?
- What fertilizer treatment increases soil microbial diversity?
- How to reduce acrylamide content in processed foods?
After the webinar all participants had the possibility to request free access to test the platform for their individual needs.
A recording of the webinar is now available on the Biomax Website or in our brand-new YouTube Channel.
31.3.2020; 3:00 p.m. (CET)
19.5.2020; 3:00 p.m. (CET)
CONTACT BIOMAX TODAY Biomax Informatics AG Robert-Koch Str. 2 D-82152 Planegg Germany
+49 89 895574-0 (Germany) +44 7832 965 326 (United Kingdom) +1 608 636 2222 (Americas and Japan)
Biomax, NeuroXM and AILANI are trademarks of Biomax Informatics AG in Germany and other countries.
Biomax Informatics AG Registered Office (Sitz der Gesellschaft): Planegg, Germany Court of Registration (Registergericht): AG München, HRB 134442 CEO (Vorstandsvorsitzender): Dr. Klaus Heumann Chairman of the Supervisory Board (Vorsitzender des Aufsichtsrats): Prof. Dr. Hans-Werner Mewes
|